NCT Number: NCT00397956
To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)
To collect clinical response data with the use of ertapenem in community acquired sepsis.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or female patients, 18 years of age or older
- Patients present with at least two of the following signs and symptom:
- fever (temperature> 38c or < 36c)
- heart rate > 90 beats/min)
- respiratory rate> 20 breaths/min)
- high white blood cell count > 12,000/ul or >10% bands)
Exclusion criteria
- Patient has a history of allergy or hypersensitivity (anaphylaxis) or serious adverse reaction to ertapenem or any carbapenem
- Patient has a poor chance of survival for more than 14 days.
- Patient has an apache ii score > 15 (see attachment 3.
- Patient has an infection caused by pathogens resistant to ertapenem
- The patient requires antibiotics other than ertapenem (such as: glycopeptides, macrolides or antifungal agents)
Treatment and study plan
Primary outcomes
-
Signs and symptoms of infection on days 3, 4, 7 and 14 during treatment
Secondary outcomes
-
Safety and Tolerability
Sponsors and collaborators
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Registry information
Official study title
An Open-Label, Single-Arm, Non-Comparative Study to Evaluate the Efficacy, Tolerability & Convenience of Invanz(TM) (Ertapenem Sodium) In the Treatment of Community-Acquired Sepsis in Adults
Important dates
- Study start
- 2004
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Nov 10, 2006
- Registry last updated
- Oct 30, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Risk Factors for Adverse Outcomes in Sepsis
NCT06541600
Infections, Inflammation
Wuhan, Hubei, China
View Trial DetailsRole of the Kallikrein-kinin System in Septic Cardiomyopathy
NCT06080282
Infections, Inflammation
Wuhan, Hubei, China
View Trial DetailsEvaluating Artificial Intelligence-Based Clinical Decision Support for Sepsis and ARDS
NCT07025096
Acute Respiratory Distress Syndrome (ARDS), Infections
Philadelphia, Pennsylvania, United States
View Trial DetailsVirtual Reality in ICU - PARTNER
NCT06876168
Acute Respiratory Failure, Infections
Lexington, Kentucky, United States
View Trial Details